Toxic epidermal necrolysis caused by multi-drug combinations: a case report

doi:10.19803/j.1672-8629.2022.02.24

Abstract

Abstract: Objective To investigate the etiology of toxic epidermal necrolysis. Methods The process of diagnosis and treatment of one case of toxic epidermal necrolysis was reviewed. The causes of serious drug adverse reactions were analyzed based on drug screening, pathogen detection and genetic detection. Results The drugs that might have caused toxic epidermal necrolysis included cefoperazone sulbactam sodium, loperamide and pantoprazole. The Narranjo score failed to distinguish suspicious drugs. The ALDEN score judged the three drugs as“probable”, “possible” and “possible”. Genetic test showed that the patient did not have any mutation of human leukocyte antigen alleles. The etiology of the patient's blood detected the fine ring virus type 16, type 27 and human herpes virus type 5, which might have increased the susceptibility to the disease. Conclusion The toxic epidermal necrolysis of this patient might have been caused by cefoperazone sulbactam sodium along with viral infection and low immunity.

Key words: Stevens-Johnson syndrome, toxic epidermal necrolysis, cefoperazone sulbactam, human leukocyte antigen allele, virus, adverse drug reaction

CLC Number:

R969.3R994.11

LIU Xuejiao, YUE Huijie, WU Yanzi, HUANG Xiaohui. Toxic epidermal necrolysis caused by multi-drug combinations: a case report[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 219-220.

References

[1] STERN RS, DIVITO SJ.Stevens-Johnson syndrome and toxic epidermal necrolysis: association, outcomes, and pathobiology-thirty years of progress but still much to be done[J]. J Invest Dermatol, 2017, 137(5): 1004-1008.
[2] SEKULA P, DUNANT A, MOCKENHAUPT M, et al.Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. J Invest Dermatol, 2013, 133(5): 1197-1204.
[3] SCHWARTZ RA, MCDONOUGH PH, LEE BW. Toxic epidermal necrolysis: part I. introduction, history, classification, clinical features, systemic manifestations, etiology,immunopathogenesis[J]. J Am Acad Dermatol, 2013, 69(2): 173.e1-13.
[4] SOTOZONO C, UETA M, NAKATANI E, et al.Predictive factors associ-ated with acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. Am J Ophthalmol, 2015, 160(2): 228-237.
[5] SCHWARTZ RA, MCDONOUGH PH, LEE BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention,treatment[J]. J Am Acad Dermatol, 2013, 69(2): 187.e1-16.
[6] JANOUK D, SIMONE C, CHIARA G, et al.Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry[J]. Pharmacoepidemiol Drug Saf, 2015, 25(2): 196-203.
[7] MOCKENHAUPT M, VIBOUD C, DUNANT A, et al.Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. TheRuroSCAR-study[J]. J Invest Dermatol, 2008, 128(1): 35-44.
[8] GOLDMAN JL, CHUNG WH, LEE BR, et al.Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement[J]. Eur J Clin Pharmacol, 2019, 75(8): 1135-1141.
[9] SASSOLAS B, HADDAD C, MOCKENHAUPT M, et al.ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case control analysis[J]. Clin Pharmacol Ther, 2010, 88(1): 60-68.
[10] PEI Y, WANG R, WANG DD, et al.Literature analysis of HLA-B*5801 polymorphisms and cutaneous adverse reactions induced by allopurinol[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(3): 154-156.
[11] LI X, YU K, MEI S, et al.HLA-B *1502 increases the risk of phenytoin or lamotrigine induced Stevens-Johnson syndrome/toxic epidermal necrolysis: evidence from a meta-analysis of nine case-control studies[J]. Drug Res (Stuttg), 2015, 65(2): 107-111.
[12] KHALAF D, TOEMA B, DABBOUR N, et al.Toxic epidermal necrolysis associated with severe cytomegalovirus infection in a patient on regular hemodialysis[J]. Mediterr J Hematol Infect Dis, 2011, 3(1): e2011004.
[13] LERCH M, MAINETTI C, TERZIROLI B, et al.Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. Clin Rev Allergy Immunol, 2018, 54(1): 147-176.
[14] WU XF, LIN Z, LI Y, et al.Retrospective analysis of 346 cases of drug eruptions[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(3): 149-153.
[15] MA ZT, GONG R, FU NS, et al.Death due to serious toxic epidermal necrolysis evoked by cefoperazone sodium and sulbactam sodium[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2017, 19(2): 127-129.
[16] LEE HY, Tharmotharampillai T, Pang SM, et al.Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in adults[J]. Int J Dermatol, 2017, 56(4): e78-e79.
[17] AMSTUTZ U, SHEAR NH, RIEDER MJ, et al.Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions[J]. Epilepsia, 2014, 55(4): 496-506.
[18] SAITO Y, STAMP LK, CAUDLE KE, et al.Clinical Pharmaco-genetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update[J]. Clin Pharmacol Ther, 2016, 99(1): 36-37.